Screening assessments will be completed within 28 days prior to
the Day 1 visit. The screening window can be extended up to 42 days in
extenuating circumstances, including the need for a liver biopsy or
additional HCV genotyping (if initial testing is inconclusive). Study
visits will occur at Screening, Day 1, and on-treatment at the end of
Weeks 1, 2, 3, 4, 5, 6, 8, 10, and 12. Following the last dose of study
medication, all subjects will complete 4-Week, 12-Week and 24-Week
Posttreatment Visits.

Screening Visit
Screening assessments will be completed within 28 days of the Day 1 visit. The screening window
can be extended up to 42 days for subjects requiring a liver biopsy, additional HCV genotyping (if
initial testing is inconclusive), or for extenuating circumstances with sponsor approval. A single
retest of screening labs is permitted only if there is reason to believe the retest value will be within accepted parameters if the initial value was either due to a sample processing error or due to an extenuating circumstance such as intercurrent infection.

https://clinicaltrials.gov/ProvidedDocs/33/NCT02738333/Prot_...
ccccccccccccccccccccccc

Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities

https://clinicaltrials.gov/ct2/show/NCT00894075